> ## Content Index
> Fetch the complete content index at: https://members.americanhealthintel.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Centene swings to $1.09B profit, raises guidance
- URL: https://members.americanhealthintel.com/2026-07-28-ledger/
- Published: 2026-07-28T16:03:39.000Z
- Updated: 2026-07-28T16:03:39.000Z
- Description: Plus: Novanta closes $1.45B Riverpoint Medical acquisition. The day's rules, money, and enforcement, sourced and tiered below.
- Author: American Health Intel

Plus: Novanta closes $1.45B Riverpoint Medical acquisition. The day's rules, money, and enforcement, sourced and tiered below.

| American Health Intel Rules · Money · Medicine · Decoded daily The Ledger Tuesday, July 28, 2026 Centene swings to $1.09B profit, raises guidance Plus: Novanta closes $1.45B Riverpoint Medical acquisition. The day's rules, money, and enforcement, sourced and tiered below. ![](https://americanhealthintel.com/email/pulse-divider.png) Earnings Confidence: High Centene, the nation's largest Medicaid managed-care insurer, swung to a 1.09 billion dollar profit this morning, a year after posting a 253 million dollar loss, as its medical costs came in far below what Wall Street expected. Its health benefits ratio, the share of premiums spent on care, fell to 89.6% from 93.0% a year ago on marketplace repricing and Medicaid rate hikes. Full-year guidance rose to adjusted EPS above $4.80\. Marketplace enrollment fell to 3.5M from 5.8M. Why it matters Centene is the country's largest Medicaid insurer, so its swing back to profit signals that the industry's 2025 cost spike may be easing, but its own numbers show a shrinking ACA marketplace book as subsidies lapse. Sources: [SEC](https://www.sec.gov/Archives/edgar/data/0001071739/000107173926000154/a20260728ex991pressrelease.htm?ref=members.americanhealthintel.com) · [Forbes](https://www.forbes.com/sites/brucejapsen/2026/07/28/centene-reports-1-billion-profit-as-health-insurers-costs-ease/?ref=members.americanhealthintel.com) Deal Confidence: High Novanta, the scientific-instruments and medical-device maker, closed a deal to buy surgical-consumables maker Riverpoint Medical for up to 1.45 billion dollars, roughly doubling its recurring medical device revenue overnight. Novanta paid $1.2 billion cash plus a $250 million milestone due in Q1 2027, about 19 times Riverpoint's 2026 EBITDA. Riverpoint makes surgical fibers for sports medicine, trauma and cardiovascular procedures. Why it matters A device maker doubling its recurring medical revenue overnight shows continued consolidation in surgical consumables, a corner of the medical device market tied to elective procedure volume. Sources: [Businesswire](https://www.businesswire.com/news/home/20260727169263/en/Novanta-Completes-Acquisition-of-Riverpoint-Medical?ref=members.americanhealthintel.com) Also today UHealth and UnitedHealthcare still without a deal, 3 days to deadline [Read](https://americanhealthintel.com/editions/2026-07-28-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#uhealth-unitedhealthcare-contract-standoff) FRONTIER SCAN: Erlanger Health signs LOI to join Prisma Health [Read](https://americanhealthintel.com/editions/2026-07-28-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#erlanger-prisma-health-affiliation-frontier-scan) Medical outpatient building M&A activity falls 26% in Q2 2026 [Read](https://americanhealthintel.com/editions/2026-07-28-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#medical-outpatient-building-q2-2026-ma-slowdown) 290Records$19.0BEnforcement12Deadlines88Rules [Read this issue + the trackers](https://americanhealthintel.com/editions/2026-07-28-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) Pick your field on the site and every story tells you what it means for you. Reply to this email and tell us what you want covered. We read everything. We show our work. We score our own calls. [Track record](https://americanhealthintel.com/ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Calendar](https://americanhealthintel.com/calendar/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Enforcement](https://americanhealthintel.com/enforcement/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [X](https://x.com/amhealthintel?ref=members.americanhealthintel.com) · [LinkedIn](https://www.linkedin.com/company/american-health-intel?ref=members.americanhealthintel.com) News and analysis, not legal, medical, coding, or investment advice.You subscribed at americanhealthintel.com · [Unsubscribe](%%{unsubscribe%5Furl}%%) |
| ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |